Inspiolto Respimat (Tiotropium, Olodaterol)

Tiotropium blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑induced constriction, while olodaterol activates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. The dual mechanism produces sustained bronchodilation, keeping the airways open and improving airflow for patients with COPD.

The prescribed dose of Inspiolto Respimat is determined by the treating physician based on the patient’s clinical condition, severity of COPD, and response to therapy. The inhaler delivers a fixed combination of tiotropium and olodaterol per actuation, and the prescriber will specify the number of inhalations and frequency appropriate for each individual.

Safety data for tiotropium and olodaterol in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To order Inspiolto Respimat, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Inspiolto Respimat combines a long‑acting muscarinic antagonist (LAMA) and a long‑acting β2‑agonist (LABA) in a single soft‑mist inhaler, offering dual bronchodilation. Compared with single‑component inhalers, it provides broader receptor coverage, potentially improving symptom control and reducing exacerbations. Its Respimat device creates a fine mist that may enhance lung deposition versus some dry‑powder inhalers, but choice of therapy should be individualized based on patient preference, technique, and clinical response.

Store at room temperature: Keep the Respimat inhaler in its original packaging, protected from moisture, direct sunlight, and excessive heat. Do not expose the device to temperatures above 30 °C for prolonged periods. The inhaler does not require refrigeration, but it should be kept upright and the cartridge should be replaced according to the manufacturer’s schedule.

Inspiolto Respimat is used by inhalation through a soft‑mist device. Before first use, the inhaler must be primed according to the instructions. The patient exhales fully, places the mouthpiece in the mouth, and inhales slowly and deeply while activating the device. After inhalation, the patient should hold their breath for about 10 seconds, then breathe out normally. The inhaler should be cleaned regularly as directed.

Serious risks include paradoxical bronchospasm, which can worsen breathing difficulty, and allergic reactions such as angioedema or anaphylaxis that require immediate medical attention. Cardiovascular effects like tachycardia, arrhythmias, or increased blood pressure may occur, especially in patients with pre‑existing heart conditions. Patients should be instructed to seek urgent care if they experience swelling of the face or throat, severe shortness of breath, or rapid heart rhythm.

Inspiolto Respimat should not be used in patients with known hypersensitivity to tiotropium, olodaterol, or any excipients of the inhaler. It is also contraindicated for acute bronchospasm or as a rescue medication. Caution is advised in individuals with severe renal impairment, uncontrolled cardiovascular disease, or those taking medications that may interact significantly, such as strong anticholinergics or beta‑blockers.